Across TCGA pan-cancer cohorts, LCE5A RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated LCE5A data layer compared with 3 for mutation status.
The strongest signal is observed in cholangiocarcinoma (CHOL), where higher LCE5A RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LCE5A expression acts as an unfavorable survival marker, although some lineages such as LGG and SARC show a favorable association.
CHOL, BRCA, and UCEC are the cancer types where LCE5A RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.